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Venezuelan (VEEV), eastern, and western equine encephalitis viruses, members of the genus Alphavirus,
are causative agents of debilitative and sometimes fatal encephalitis. Although human cases are rare,
these viruses pose a threat to military personnel, and to public health, due to their potential use as
bioweapons. Currently, there are no licensed therapeutics for treating alphavirus infections. To address
this need, small-molecules with potential anti-alphavirus activity, provided by collaborators, are tested
routinely in live alphavirus assays utilizing time-consuming virus yield-reduction assays. To expedite
the screening/hit-conﬁrmation process, a cell-based enzyme-linked immunosorbent assay (ELISA) was
developed and validated for the measurement of VEEV infection. A signal-to-background ratio of >900,
and a z-factor of >0.8 indicated the robustness of this assay. For validation, the cell-based ELISA was
compared directly to results from virus yield reduction assays in a single dose screen of 21 compounds.
Using stringent criteria for anti-VEEV activity there was 90% agreement between the two assays (compounds displaying either antiviral activity, or no effect, in both assays). A concurrent compound-induced
cell toxicity assay effectively ﬁltered out false-positive hits. The cell-based ELISA also reproduced successfully compound dose–response virus inhibition data observed using the virus yield reduction assay.
With available antibodies, this assay can be adapted readily to other viruses of interest to the biodefense
community. Additionally, it is cost-effective, rapid, and amenable to automation and scale-up. Therefore, this assay could expedite greatly screening efforts and the identiﬁcation of effective anti-alphavirus
inhibitors.
Published by Elsevier B.V.

1. Introduction
The majority of viruses within the genus Alphavirus are nonpathogenic to humans. However, select alphaviruses can cause
severe disease in humans and represent a signiﬁcant threat to public health. Venezuelan (VEEV), eastern (EEEV), and western equine

Abbreviations: BSA, bovine serum albumin; CHIKV, Chikungunya virus;
CPE, cytopathic effect; EEEV, eastern equine encephalitis virus; ELISA, enzymelinked immunosorbent assay; HRP, horseradish peroxidase; IC50 , 50% inhibitory
concentration; MAb, monoclonal antibody; MOI, multiplicity of infection; PBS,
phosphate-buffered saline; pfu, plaque-forming units; RT, room temperature; S/B,
signal to background ratio; SD, standard deviation; TCID50 , tissue culture infectious
dose 50; TrD, Trinidad donkey strain of VEEV; USAMRIID, United States Army Medical Research Institute of Infectious Disease; VEEV, Venezuelan equine encephalitis
virus; WEEV, western equine encephalitis virus.
∗ Corresponding author at: U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702, United States.
Tel.: +1 301 619 4742.
E-mail addresses: pamela.j.glass.civ@mail.mil, pam.glass@us.army.mil
(P.J. Glass).

encephalitis (WEEV) viruses, are causative agents of debilitative,
acute, and sometimes fatal encephalitis in North, Central, and South
America (Strauss and Strauss, 1994). Chikungunya virus (CHIKV),
an old world alphavirus, causes chikungunya fever, a febrile illness characterized by severe arthralgia (Schwartz and Albert, 2010;
Thiboutot et al., 2010). In 2005, a large outbreak of chikungunya
fever began in La Reunion, an island in the Indian Ocean. This outbreak caused over 300,000 cases and 237 deaths (Higgs, 2006), and
subsequently spread to India where over 1.5 million cases were
recorded. These alphaviruses are naturally maintained in a zoonotic
cycle between nonhuman vertebrate hosts and hematophagous
mosquito vectors. Natural human cases occur through the bite of an
infected mosquito. VEEV, EEEV, and WEEV are additionally recognized as candidates for use as biological weapons, and are classiﬁed
as category B pathogens by the Centers for Disease Control and Prevention and The National Institutes of Health (Reichert et al., 2009).
Given this threat, and the recent reemergence of CHIKV, there is a
critical need for an effective, broad-spectrum anti-alphavirus therapeutic. Currently, there are no licensed drugs available for the
treatment of VEEV, EEEV, WEEV, or CHIKV infections.

0166-0934/$ – see front matter. Published by Elsevier B.V.
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Alphavirus virions are small, spherical particles ∼70 nm in diameter, with a nucleocapsid core surrounded by a host-derived lipid
membrane (Strauss and Strauss, 1994). The nucleocapsid is assembled from 240 copies of viral capsid protein (C). Glycoprotein
spikes, composed of trimers of viral E1/E2 heterodimers are embedded in, and extend from the viral membrane. To address the
need for alphavirus therapeutics, Prosetta Antiviral, Inc. developed
a cell-free, high-throughput screen to identify compounds that
interfere with alphavirus capsid assembly (manuscript in preparation). Preliminary hits from this screen, as well as small-molecules
from other collaborators, are routinely tested for anti-alphavirus
activity using standard, time-consuming, and labor-intensive virus
yield-reduction assays (standard plaque assay or tissue culture
infectious dose 50 [TCID50 ] assay). Although these traditional virus
titer assays can validate hits from preliminary screens, their use
represents a signiﬁcant bottle-neck in the hit-conﬁrmation process.
The present study describes the development and validation
of a cell-based ELISA for the detection and quantitation of
VEEV infection in cell monolayers, and its suitability for use in
high-throughput screening applications. The ELISA reproduced
accurately data from a virus yield reduction assay in a singledose screen of 21 test compounds with potential anti-alphavirus
activity, and can also be used in the context of compound dose
curve analyses and IC50 (50% inhibitory concentration) calculations.
This assay is signiﬁcantly less time-, labor-, and material-intensive
than virus yield reduction measurements using standard plaque
assay or TCID50 assay. A high signal-to-background ratio and high
z-factor value indicate that the cell-based ELISA method can be
adapted successfully for use in a high-throughput scenario. Based
on these data, the VEEV cell-based ELISA is suitable for, and will
expedite screening efforts to identify anti-VEEV small-molecule
inhibitors.
2. Materials and methods
2.1. Virus and cells
Virus infections were carried out with VEEV (subtype IA/B)
Trinidad donkey (TrD) strain obtained from USAMRIID archives.
Vero cells were obtained from USAMRIID Virology Department cell
culture core lab, and were maintained in Eagle’s Minimum Essential
Medium (EMEM) supplemented with non-essential amino acids,
and 10% fetal bovine serum (Life TechnologiesTM , Grand Island, NY).
Cells were incubated at 37 ◦ C, in a humidiﬁed incubator, with 5%
CO2 .
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E2 protein were detected with Super Signal ELISA Pico chemiluminescence substrate (Thermo Scientiﬁc, Waltham, MA) (5 min
incubation, RT), and a Spectramax M5 plate reader (Molecular
Devices, Sunnyvale, CA).
For the compound screen using the ELISA, compounds were
diluted and mixed with VEEV virions for 4 h, 37 ◦ C. The compound/virus mixture was then added to Vero cells plated in
black 96-well plates. Cells were incubated in the presence
virus/compound for 18 h. Cells were then ﬁxed and processed
for ELISA as described above. Baﬁlomycin A1 (Enzo Life Sciences,
Farmingdale, NY) was used as a positive control VEEV-inhibitory
compound in the ELISA (Hunt et al., 2011).

2.3. Cell viability
Compounds were diluted to the indicated concentrations in
complete media and added to Vero cells in black 96-well plates, in
100 l ﬁnal volume. Cells were incubated for 48 h, at 37 ◦ C, and then
moved to RT for 30 min. Cell Titer Blue reagent (20 l, Promega,
Madison, WI) was added to cell culture supernatant in each well,
and incubated for 3 h at 37 ◦ C. Fluorescence was then measured in
each well with a Spectramax M5 plate reader.

2.4. Virus yield reduction assay
Vero cells in 24-well plates were infected with VEEV TrD (MOI
10), for 1 h, 37 ◦ C, in 100 l volume. After infection, the virus
inocula were removed, cells were washed twice with serum-free
medium. Complete medium (2% FBS + penicillin 0.5 mg/ml, streptomycin 0.5 mg/ml) containing compound was then added to the
cells (triplicate wells for each compound/concentration), and incubated for 24 h, 37 ◦ C. Cell culture supernatants from each well of
the 24-well plate were collected. Virus yield was determined by
TCID50 assay. Brieﬂy, supernatants were diluted in 96-well plates
(ﬁve replicate dilution series for each well of the 24-well plate).
A 10-fold dilution series was generated from 10−1 to 10−8 . The
serial dilutions were then transferred to Vero cells in 96-well
plates, and incubated for 6 d. Medium was removed and cells
were ﬁxed and stained with 0.05% crystal violet in 3.7% formaldehyde for 30 min at RT. Stain was removed and cells were rinsed
with water and air dried. Cytopathic effect (CPE) was observed
by visual inspection. The two virus dilutions where CPE transitioned from >50% (three or more replicate wells with CPE) to
<50% of replicates with CPE were recorded. TCID50 was determined by calculations described previously (Reed and Muench,
1938).

2.2. Cell-based ELISA
2.5. Statistics
Conﬂuent Vero cell monolayers in black 96-well plates (Greiner
Bio-one, Monroe, NC) were infected with VEEV TrD at various multiplicities of infection (MOIs). MOI calculations utilized a cell number
(based on previous cell counts) of 4 × 104 Vero cells per conﬂuent
well in a 96-well plate. Virus was diluted in complete medium and
was added to cells in 50 l volume. After 1 h virus was removed
and fresh medium added. At indicated time points after infection,
cells were ﬁxed in 3.7% formaldehyde in phosphate-buffered saline
(PBS), at 4 ◦ C for 18–24 h. Cells were washed in PBS and then blocked
with 3% bovine serum albumin (BSA, Sigma–Aldrich, St. Louis, MO)
in PBS for 1 h at room temperature (RT). Anti-VEEV E2 1A4A-1
monoclonal antibody (Roehrig and Mathews, 1985) (1 mg/ml) was
diluted in PBS + 3% BSA and added to cells for 2 h, RT. After washing
with PBS, cells were incubated with goat anti-mouse horseradish
peroxidase (HRP) secondary antibody (Invitrogen, Grand Island,
NY) diluted in PBS + 3% BSA for 1 h, RT. Cells expressing VEEV

For replicate 96-well plates containing cells infected with
VEEV (positive controls) or not infected (negative controls), ttests were used to compare plate 1 to plate 2 on each of two
days to assess plate-to-plate differences. For replicate 96-well
plates containing cells infected with VEEV or not infected, t-tests
were used to compare plates from day 1 to plates from day 2
to assess day-to-day differences. For 96-well plates containing
cells infected with VEEV in the presence of a cohort of 21 potential anti-VEEV compounds, the correlation coefﬁcient (r) between
the virus yield reduction assay and the cell-based ELISA was
calculated, and used to determine if the correlation was statistically signiﬁcant. Spearman’s rank correlation was utilized. Using
the cell-based ELISA, and eight-point dose curve was analyzed
for compound 22. The IC50 value was calculated using probit
analysis.
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A

3. Results

3.2. Comparison of cell-based ELISA to virus yield reduction assay
in a limited screen for potential anti-VEEV small-molecule
inhibitors
A cohort of potential anti-VEEV compounds was supplied to
USAMRIID by Prosetta Antiviral, Inc. These compounds were subsequently tested for anti-VEEV activity using a virus yield reduction
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In previous experiments, monoclonal antibody (MAb) 1A4A-1,
directed against VEEV E2 protein, has proven effective at detecting
viral antigen in immunoﬂuorescence assays (Parker et al., 2010).
This antibody was evaluated for performance in a cell-based ELISA
format for the detection and quantitation of VEEV-infected Vero
cell monolayers in 96-well plates. MAb 1A4A and HRP-conjugated
secondary antibodies were titrated to determine optimal concentrations yielding maximized signal/background ratios (S/B). Vero
cells were infected with VEEV, at an MOI of 0.01 plaque-forming
units per cell (pfu/cell), and incubated for 18 h. Cells were then ﬁxed
and processed for cell-based ELISA. Four dilutions of MAb 1A4A
were tested with four dilutions of HRP-conjugated secondary antibody. After addition of the HRP substrate, luminescent signal was
recorded with a plate reader. A primary antibody dilution of 1:4000,
with a secondary antibody dilution of either 1:5000 or 1:10,000
yielded S/B ratios >900. All subsequent experiments were carried
out using a 1:4000 dilution of 1A4A, and HRP-conjugated secondary
antibody diluted 1:10,000.
Experiments were performed to determine the appropriate
virus dose (MOI) and infection time point to be used in smallmolecule screening efforts. Optimal parameters are necessary for
the detection of inhibition of infection (virus spread) in the presence of compounds with anti-VEEV activity. These parameters are
especially relevant when screening for inhibitors of viruses with
extremely fast replication cycles, such as VEEV (4 h) (Strauss and
Strauss, 1994). Vero cells were infected with VEEV at MOIs of 0,
0.0001, 0.001, 0.01, 0.1, and 1 pfu/cell. Infected cells were incubated
for 6, 18, or 24 h before ﬁxation and processing for cell-based ELISA
(Fig. 1A). A low level of infection was detected at 6 h using MOIs
of 1 and 0.1. In contrast, the luminescent signal was near maximum for most MOIs tested 24 h after infection. When measured
at 18 h after infection, the ELISA signal was virus dose-dependent,
and did not reach maximum levels (compared to 24 h data). High
variability was consistently seen at the very low MOI of 0.0001, as
some replicate wells had infected cells and others no infection was
detected. Based on the 18 h virus dose–response curve, subsequent
small-molecule screening experiments were performed using MOI
0.01, infected for 18 h.
The suitability of the ELISA as an assay for high-throughput
screening was investigated next. Cells in two replicate 96-well
plates were infected with VEEV (MOI 0.01, 18 h), or not infected,
on two separate days (four plates total in analysis). Cells were ﬁxed
and processed for ELISA (Fig. 1B). T-tests were utilized to assess
plate-to-plate and day-to-day variability. Brieﬂy, t-tests compared
ELISA luminescence signal between plate 1 and 2 for each day
(experiment 1 and 2) for negative controls and positive controls
separately and combined. Likewise t-tests compared luminescence
signal between plates of experiments 1 and experiment 2. In each
case, the resulting p-values indicate that no statistically signiﬁcant
differences were found (not shown). This analysis demonstrated
low plate-to-plate and day-to-day variability for the VEEV cellbased ELISA. Using averaged data from all four plates, a z-factor
of 0.82 was calculated for this assay (Table 1).

Luminescence

350000

3.1. Optimization of a VEEV cell-based ELISA and characterization
of infection kinetics

200000

Exp 1

Exp 2

150000
100000
50000
0

No Virus

+ VEEV

Fig. 1. Evaluation and optimization of a cell-based ELISA for the quantitation of
VEEV infection in 96-well plates. (A) A virus dose response and time course experiment was performed to examine the kinetics of VEEV infection as measured by the
cell-based ELISA. Vero cells were infected at the indicated MOIs for 6, 18, or 24 h.
Luminescent ELISA signal is plotted for each MOI and time point. (B) Determination
of plate-to-plate and day-to-day variability of cell-based ELISA data. Duplicate plates
were infected with VEEV MOI 0.01 for 18 h, or not infected, and then processed for
ELISA. Two independent experiments (Exp 1 and Exp 2) were carried out on separate days. For each experiment, luminescence data for each well on duplicate plates
were averaged and plotted.

assay and the cell-based ELISA. For virus yield reduction assay, cells
were infected with VEEV (MOI 10) for 1 h. After incubation, excess
virus was removed, cells were washed with serum-free medium,
and complete medium containing compound (10 M), or vehicle
control (dimethyl sulfoxide, DMSO, ﬁnal concentration 0.1%) was
added. Infected cells were incubated with compound for 24 h. The
cell culture supernatant was then collected and VEEV titer measured by TCID50 assay (Fig. 2A). Several compounds reduced VEEV
virus yield by >4 logs. Compounds with intermediate anti-VEEV
activity, or no activity, were also detected (Fig. 2A and Table 2).
Previous experiments demonstrated that DMSO does not inﬂuence
VEEV titer in this assay (not shown). This same cohort of compounds was also tested for anti-VEEV activity using the cell-based
ELISA. A screening protocol was established that would detect
effectively compounds that act directly on virions, or that act on
intracellular protein targets. To this end, VEEV virions were mixed
Table 1
Z-factor determination for VEEV cell-based ELISA.
Wells

n

Meana

SD

Z

Non-infected
VEEV-infected

96
288

2.65
5.37

0.14
0.02

0.82

SD, standard deviation.
a
Log10 -transformed luminescence values.
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Table 2
Results of small-molecule screen. Correlation between ELISA and virus yield reduction assay data.
Compound

ELISA (% inhibition)

TCID50 (decrease in titer)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

>80%
<20%
>80%
>80%
>80%
<20%
>80%
>80%
>50%
>80%
<20%
>80%
<50%
>80%
>80%
>80%
>80%
>80%
<50%
>80%
>80%

>4 log
∼1 log
>2 log
>4 log
>4 log
No decrease
>4 log
>4 log
∼3 log
>4 log
No decrease
>4 log
<2 log
>4 log
>4 log
>2 log
>4 log
>4 log
<2 log
>4 log
>4 log

with individual compounds and incubated at 37 ◦ C for 4 h. The
virion/compound mixture (10 M compound ﬁnal concentration)
was then added to Vero cell monolayers in a 96-well plate. This
infection mixture remained on the cells for 18 h. Cells were then
ﬁxed and processed for ELISA. The data obtained with this assay
closely mirrored those of the virus yield reduction assay (Fig. 2B
and Table 2). Of the 21 compounds tested, 15 compounds reduced
ELISA signal by >80% of control (infected cells without compound
treatment). Each of these hits reduced virus yield by >2 logs, with
most (13/15) showing a >4 log reduction in virus titer. Spearman’s
rank correlation was utilized to evaluate the relationship between
TCID50 titers and ELISA luminescence for the cohort of potential
anti-VEEV compounds. The resulting correlation coefﬁcient was
r = 0.88, and the corresponding p-value was p < 0.0001, indicating
that there is evidence of a linear relationship between the virus
yield reduction and ELISA results (Fig. 2C). Overall, the cell-based
ELISA for quantitation of VEEV infection accurately recapitulated
virus yield reduction assay titer measurements made with TCID50
assay.
The observed compound-dependent reduction in ELISA signal,
or reduction in virus yield, could be the result of potent VEEV inhibition, or the result of compound-induced cell toxicity. Compounds
producing signiﬁcant toxicity could present as false-positives in
either of these assays. To help identify and ﬁlter out false positives,
at the time of infection for the ELISA, cells in a replicate plate were
exposed to compound without virus infection. Cells were incubated
for 48 h at 37 ◦ C. Cell viability was then measured using Cell Titer
Blue assay (Fig. 2D). Most compounds did not produce signiﬁcant
toxicity, as measured by this particular assay. Compound 15 was
clearly toxic and reduced the viability-dependent ﬂuorescent signal to 9% of the control wells. These data suggest that compound 15
is a false-positive hit in the ELISA and virus yield reduction assays,
and would be ﬁltered out of further analysis. Two other compounds
Fig. 2. Comparison of virus yield reduction assay and cell-based ELISA in a
small screen to identify anti-VEEV compounds. (A) Twenty-one small-molecule
compounds were screened for the ability to reduce VEEV yield. Titers in cell culture
supernatants were determined by TCID50 assay. Cells were infected with VEEV in
24-well plates for 1 h. After the infection period, medium was added containing
compound (10 M), or DMSO as a control (DM). VEEV titer (TCID50 /ml) was measured in cell culture supernatants 24 h after the start of infection, and was plotted
for each compound. (B) The same group of compounds was examined for anti-VEEV
activity using the cell-based ELISA. Virions were pre-treated with compound, or
not treated (NT) and subsequently used to infect cells. The compound + virus mixture remained on cells through the 18 h incubation period. DMSO (DM) had no effect

on VEEV infection-dependent ELISA signal. Baﬁlomycin (Baf, 1 M) was used as a
positive control and effectively inhibited VEEV infection. Several compounds dramatically reduced ELISA signal after VEEV infection. (C) Average ELISA signal vs.
average TCID50 titer for each of 21 compounds. For each compound, ELISA luminescence data and TCID50 titer data were log10 transformed and plotted on a scatter plot.
The linear regression line is shown. (D) Cell toxicity assay. Vero cells were treated
with each compound (10 M), DMSO, or baﬁlomycin (1 M) for 48 h. Cell viability
was then measured using Cell Titer Blue assay. Viability-dependent ﬂuorescent signal was recorded and plotted for each treatment. Most compounds had little effect
on cell viability as measured by this assay.
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screen. These data also suggested that the ELISA could detect
compounds with intermediate or modest antiviral activity. The performance of this assay was examined in the context of a compound
dose–response experiment. Compound 22 demonstrated a dosedependent inhibition of VEEV production in Vero cells as measured
by the virus yield reduction assay (Fig. 3A). Treatment of cells with
200 nM compound 22 produced an ∼2 log reduction in VEEV titer
24 h after infection compared to DMSO-treated control cells. This
virus inhibition was lost at a compound concentration of 5 nM.
Using the cell-based ELISA and compound 22, an 8-point dose curve
analysis was performed (Fig. 3B). Starting with 500 nM, a 2.5-fold
compound dilution series was generated and tested. Cells were
treated with compound and processed for ELISA as described for the
single-dose screen. Baﬁlomycin A1 was used as a control and effectively inhibited VEEV infection in this assay. The cell-based ELISA
method detected dose-dependent anti-VEEV activity of compound
22. Using DMSO as the positive control, an IC50 value of 50 nM was
calculated for this compound. The same compound dilutions were
added to cells, without virus infection, and incubated for 48 h. At
this time point no cellular toxicity was detected with this assay at
any compound concentration tested (Fig. 3C).

4. Discussion

Fig. 3. Comparison of virus yield reduction assay and cell-based ELISA in a dose
response analysis of a non-toxic compound with anti-VEEV activity. (A) Compound
22 was tested at three concentrations for the ability to decrease VEEV yield. A dosedependent inhibition of VEEV, compared to DMSO control (DM), was observed. (B)
An 8-point dose response for compound 22 was tested for VEEV inhibition with
the cell-based ELISA. DMSO (DM) had little or no effect, while baﬁlomycin (Baf)
signiﬁcantly inhibited VEEV. Treatment of cells with compound 22 resulted in a
dose-dependent inhibition of VEEV infection. (C) Cell Titer Blue viability assay after
48 h treatment with several doses of compound 22. No compound toxicity was
detected with this assay.

(10 and 17) produced a viability signal <80% of control cells, and
should be considered potential false-positives.
3.3. Dose-dependent anti-VEEV activity of compound 22
measured with virus yield reduction assay and ELISA
The VEEV-speciﬁc cell-based ELISA effectively detected smallmolecule compounds with anti-VEEV activity in a single dose

Screening assays to identify small-molecules with antiviral
activity can take several forms, each with their own advantages
and disadvantages. On one end of the spectrum are in vitro cell-free
biochemical screens identifying inhibitors of a known and highly
puriﬁed protein target with a deﬁned activity. Knowing the protein
target of identiﬁed inhibitors greatly facilitates downstream drugdevelopment efforts. However, the narrow focus of these assays,
searching for inhibitors of one speciﬁc protein, can also be described
as a disadvantage. Information regarding cell permeability or toxicity is also not readily available. Biochemical screens are typically
adapted easily to automation in 384- or 1536-well plate format,
achieving true high-throughput status, and do not require biosafety
level-3 (BSL-3) or BSL-4 high containment laboratories and the
restrictions that go along with working in that environment. This
study reports a cell-based screening strategy on the other end of the
spectrum, directly identifying inhibitors of authentic, pathogenic
VEEV.
In the cell-based ELISA screen described herein, the target of
any effective inhibitors is not known. However, this experimental
design allows investigators to cast a wide net, potentially identifying compounds that act directly on viral proteins, or on host
proteins. Additionally, compounds acting at any stage of the viral
lifecycle, from initial attachment to release of nascent viral particles
can be identiﬁed. In this assay, effective compounds, by deﬁnition,
have access to cellular and viral proteins. Cell toxicity data can
be obtained easily by running viability assays on duplicate plates,
but without virus infection. This strategy does require BSL3 containment. While it is possible to carry out initial large screens in
BSL1 or BLS2 laboratories using alternative viral reagents, such as
pseudotyped virus, attenuated viruses (i.e. VEEV vaccine strain TC83), or non-pathogenic viral replicon particles (VRPs), hits must
ultimately be tested against authentic virus. By screening directly
against wild-type pathogenic VEEV, the lead-hit generation process
is expedited greatly.
A possible disadvantage to a cell-based ELISA screening format
is the requirement of a suitable antibody detecting viral antigen. These reagents are not readily available for some viruses.
The ELISA format is also more labor intensive than other possible
screening strategies for alphavirus inhibitors. For example, most
alphavirus infections produce a pronounced cytophathic effect
(CPE) in infected cells. This virus-induced loss of cell viability, or

K.B. Spurgers et al. / Journal of Virological Methods 193 (2013) 226–231

prevention of cell death by effective small-molecule inhibitors, can
be measured easily by common cell viability assays. Many of these
assays require the addition of only a single reagent to the cell culture, a short incubation time before reading the assay, and are
performed easily in 96- or 384-well plates. However, these assays
produced much lower signal-to-background ratios and z-factors
compared to the cell-based ELISA. The detection of a signiﬁcant
loss of cell viability has also required either high MOIs or long
post-infection incubation times before reading the assay (72–96 h,
data not shown). Compounds showing signiﬁcant but not complete
inhibition of VEEV infection were detected more easily with the
cell-based ELISA compared to several viability assays tested (not
shown).
A small number of screens utilizing diverse methodologies to
identify inhibitors of alphavirus infection have been reported. For
example, in vitro cell-free biochemical screens can be employed to
identify inhibitors of puriﬁed viral proteins (when protein activity
is known and amenable to assay development). This approach has
been applied to Semliki Forest virus (SFV) nsP1 protein (Lampio
et al., 1999). SFV nsP1 has methyltransferase activity, and is
involved in the capping of viral RNAs. Lampio et al. screened 58
cap analogs for the ability to inhibit nsP1 methytransferase activity.
Several inhibitors were identiﬁed with Ki values 40–400 M. The
authors did not report cell toxicity testing or activity against live
virus in cell culture. Another cell-free approach, possible when viral
protein structural information is available, is in silico compound
screening. Using molecular modeling, compounds were designed
and synthesized that target the hydrophobic binding pocket of SINV
capsid protein (Kim et al., 2005). Select compounds inhibited virus
production effectively and were not toxic to uninfected BHK cells.
Cell-based assays reported in the literature include WEEV replicons and SINV expressing luciferase as a marker protein (Peng et al.,
2009; Pohjala et al., 2008).
Although screens for anti-alphavirus inhibitors can take several
forms, identiﬁed compounds must be tested ultimately for activity against authentic, wild-type, pathogenic virus in cell culture
experiments. Although plaque assay remains a gold standard in the
eyes of many investigators, this technique is time-consuming, labor
intensive, and is not well suited for testing a large number of compounds, and generating detailed dose response curves. The VEEV
cell-based ELISA described here does not rely on the use of nonpathogenic alphaviruses, reporter systems, recombinant viruses,
or replicons. Additionally, the assay does not require overly expensive or unwieldy equipment that is difﬁcult to introduce, maintain,
and use in a high-containment laboratory setting. With available
antibodies, this assay can be adapted readily to other viruses of
interest to the biodefense community. Antibodies detecting EEEV
and WEEV glycoproteins for use in this ELISA assay format have
also been validated. Additionally, the assay is cost effective, rapid,

231

and amenable to automation and scale-up. Therefore, this assay
could expedite screening efforts and the identiﬁcation of effective
anti-alphavirus inhibitors greatly.
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